Zen Chu

Zen Chu believes that now is the best time in history for healthcare entrepreneurs and engineers to create the data, systems, and products to help medicine scale and serve more patients with higher quality at lower cost. He created and teaches the MIT Healthcare Ventures graduate courses within the pioneering Health Science & Technology (HST) program, a joint initiative between MIT, Harvard Medical School, and the Boston academic hospitals.

As faculty director for the HackingMedicine.MIT.edu health innovation leadership initiatives, Zen mentors physician entrepreneurs, early-stage startups and health corporations adapting to global digital healthcare transformation, changing healthcare incentives, growth in emerging markets, and new disruptive technologies that re-engineer medicine.

As Managing Director of Accelerated Medical Ventures, Zen specializes in building early-stage medical technology and healthcare service companies, usually serving as co-founder and first investor. AMV’s portfolio spans Boston, Silicon Valley, and China, including PillPack.com, Figure1.com, 3D-Matrix Medical [JASDAQ: 7777], Curoverse Genomics, PathFinder Regenerative Medicine [OTCQB: PFND], BitGym.com, DirectDermatology.com, and a few companies still in stealth mode.

Alongside four world-renowned MIT biomaterials professors, Zen co-founded 3D-Matrix Medical Inc., serving as the first CEO for the venture-backed MIT regenerative medicine company whose injectable gel drug delivery products are treating patients and enabling new regenerative medicine research, with a successful IPO in 2011. He has managed and led new ventures for Harvard Medical School, Harvard’s Wyss Institute for Bioengineering, NetVentures, and Hewlett-Packard.

Zen earned a Masters of Public & Private Management from Yale University and a BS in biomedical/electrical engineering from SMU. He’s married to a serial entrepreneur/venture investor and they are raising three aspiring entrepreneurs in Brookline, MA.

Areas of expertise: Entrepreneurship, Healthcare Ventures, Medical Devices, Angel Investment

return to professional advisors